You have 9 free searches left this month | to do more

empagliflozin

Empagliflozin is a drug used to treat Diabetes Mellitus, Type 2, Healthy, Heart Failure, and other conditions. Empagliflozin is being actively studied in 30 studies and prior, has been studied in 58.

Top SponsorsTop SitesTop Investigators
Boehringer IngelheimEast Coast Institute for Research, LLCAnton Borisov
EMSThe University of North Carolina at Chapel HillCHEOL WHAN LEE, M.D., Ph.D
Getz Pharma4. Military Clinical Hospital with Polyclinic SP ZOZCaroline M Kistorp
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Empagliflozin and Atrial Fibrillation Treatment
Not yet recruiting
  • Atrial Fibrillation
  • +3 more
  • Empagliflozin
  • Placebo
  • Acquaviva Delle Fonti, Bari, Italy
    Miulli General Hospital
2021-04-01
Apr 1, 2021
O
Empagliflozin in Adolescent Diabetes
Not yet recruiting
  • type1diabetes
  • Empagliflozin
  • Columbus, Ohio
    Ohio State University
2021-06-07
Jun 7, 2021
H
Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin
Recruiting
  • Glycogen Storage Disease Type IB
  • Empagliflozin
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
2021-08-08
Aug 8, 2021
C
Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia
Not yet recruiting
  • Glucose 6 Phosphatase Deficiency
  • Empagliflozin
  • Warsaw, Poland
    The Children's Memorial Health Institute
2021-06-18
Jun 18, 2021
B
Comparative Effectiveness of Empagliflozin in the US
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +2 more
  • Boston, Massachusetts
    Bringham Women Hospital
2021-10-04
Oct 4, 2021
U
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD). - 2020
Completed
  • End Stage Renal Disease
  • Empagliflozin
  • Placebo
  • Pisa, Italy
    Department of Endocrinology and Metabolism, University of Pisa
2021-09-13
Sep 13, 2021
B
A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017 - 2018
Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Empagliflozin
  • Stockholm, Sweden
    Boehringer Ingelheim AB
2021-07-21
Jul 21, 2021
C
Head-to-head Comparison of Empagliflozin and Dapagliflozin
Active, not recruiting
  • Type2 Diabetes
  • Cheonju, Chungcheongbuk-do, Korea, Republic of
    Chungbuk National University Hospital
2021-05-14
May 14, 2021
H
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes - 2020
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Placebo
  • Hellerup, Denmark
    Center for Diabetes Research, Gentofte Hospital
2021-06-09
Jun 9, 2021
B
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists - 2021
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +3 more
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
2021-10-07
Oct 7, 2021
U
Empagliflozin and Cardiac Remodelling in People Without Diabetes
Recruiting
  • Cardiovascular Diseases
  • Left Ventricular Hypertrophy
  • Empagliflozin
  • Placebo
  • Toronto, Ontario, Canada
  • +3 more
2021-06-14
Jun 14, 2021
H
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
Recruiting
  • Acromegaly
  • Cardiomyopathies
  • Empagliflozin
  • Shanghai, Shanghai, China
    Huashan Hospital
2020-08-17
Aug 17, 2020
B
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Liraglutide in the Occurrence of Serious Cardiovascular Disease
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Aarhus, Denmark
    Department of Clinical Epidemiology - Aarhus Unversiteteshospita
2021-10-04
Oct 4, 2021
I
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). - 2020
Completed
Has Results
  • Cardiovascular Diseases
  • Empagliflozin
  • Placebos
  • New York, New York
    Mount Sinai Heart - Icahn School of Medicine at Mount Sinai
2021-03-02
Mar 2, 2021
N
A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Recruiting
  • Crohn's Disease
  • +2 more
  • Empagliflozin
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-10-14
Oct 14, 2021
B
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations - 2021
Completed
  • Diabetes Mellitus, Type 2
  • Placebo
  • Empagliflozin
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
2021-07-15
Jul 15, 2021
H
Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin
Not yet recruiting
  • Type 2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Clinical Pharmacology, Asan Medical Center
2020-06-11
Jun 11, 2020
J
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics - 2020
Completed
  • Diabetes Mellitus, Type 2
  • Diastolic Dysfunction
  • Empagliflozin
  • Placebo
  • Mainz, Germany
    Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Ze
2021-04-16
Apr 16, 2021
M
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Active, not recruiting
  • NASH
  • +7 more
  • MET409 Active
  • +2 more
  • Fort Myers, Florida
  • +1 more
2021-05-28
May 28, 2021
R
EMPA Acute Heart Failure - 2020
Terminated
  • Diabetes Mellitus, Type 2
  • Acute Heart Failure
  • Empagliflozin
  • Placebo
  • Aachen, NRW, Germany
    Department of Internal Medicine I RWTH Aachen University Hospita
2021-03-09
Mar 9, 2021
P
Empagliflozin and Sympathetic Nerve Traffic - 2020
Completed
  • Type 2 Diabetes Mellitus
  • Empagliflozin
  • Hydrochlorothiazide 25 mg
  • Neuss, North Rhine-Westphalia, Germany
    Profil Institut für Stoffwechselforschung GmbH
2020-07-13
Jul 13, 2020
Y
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects - 2019
Completed
  • Heart Failure
  • Type II; Diabetes
  • Empagliflozin
  • Placebo Oral Capsule
  • New Haven, Connecticut
    Yale New Haven Hospital
2020-06-24
Jun 24, 2020
H
Drug Interaction Study Between Dorzagliatin and Empagliflozin - 2020
Completed
  • Patients
  • Hackensack, New Jersey
    Frontage Clinical Services Inc.
2020-03-24
Mar 24, 2020
B
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes - 2019
Completed
Has Results
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Mahlow, Germany
    Diabetes Agenda 2010 GmbH
2021-03-26
Mar 26, 2021
B
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study - 2019
Completed
Has Results
  • Diabetes Mellitus, Type 1
  • +2 more
  • Empagliflozin
  • +2 more
  • Toronto, Ontario, Canada
    Toronto General Hospital
2020-07-23
Jul 23, 2020